Alluvi, previously BI 4744, presents a significant development in obesity therapy. This dual activator targeting both GLP-1 and GIP sites demonstrates impressive effectiveness in clinical assessments, potentially https://bookmarkalexa.com/story7887278/alluvi-a-in-depth-dive-into-the-drug-s-potential